Epigenomics AG To Participate In Investor Conferences
11/15/2016 9:15:37 AM
Berlin (Germany) and Germantown, MD (U.S.A.), November 14, 2016 -
Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today
announced that Greg Hamilton, Chief Executive Officer, will participate in
the following investor conferences:
- Canaccord Genuity Medical Technologies & Diagnostics Forum, Thursday
November 17, 2016, New York, Westin New York Grand Central,
Presentation: 10:00 am (EST)
- German Equity Forum 2016, Tuesday, November 22, 2016, Frankfurt,
Sheraton Frankfurt Airport Hotel, Presentation: 5:00 PM (CET)
- goetzpartners Interdisciplinary Oncology Insight Symposium, November
29, 2016, London, Le Meridien Piccadilly, Panel discussion: 2:00 PM
Epigenomics is a molecular diagnostics company focused on blood-based
detection of cancers using its proprietary DNA methylation biomarker
technology. The company develops and commercializes diagnostic products
across multiple cancer indications with high medical need. Epigenomics'
lead product, Epi proColon, is a blood-based screening test for the
detection of colorectal cancer. Epi proColon has received approval from the
U.S. Food and Drug Administration (FDA) and is currently marketed in the
United States, Europe, China and selected other countries. Epigenomics'
second product, Epi proLung(R), is in development as a blood-based test for
lung cancer detection.
For more information, visit www.epigenomics.com.
comments powered by